PETX– Aratana Therepeutics Inc is a pet therapeutics company which manufactures and distributes bio pharmaceutical products for pets. The stock rose 5% during after-hours yesterday.
PETX- Aratana Therepeutics Inc
|Fundamentals||Previously closed at||5.19|
|Analysts opinion||PETX has been granted its first FDA approval for Galliprant which controls the pain and inflammation with Osteoarthritis in dogs. Analysts have a consensus target price of $11.83 for the stock. The shares surged intraday upto its resistance at $6.17 and closed at 5.19. If the resistance levels are crossed, the stock may see a share price of $10.|
|Sentiments||Due to the news, the stock rose 5% yesterday and is expected to be bullish.|
|Social Media Pulse||The stock has 100% higher chatter than usual.|